Core Scientific, Inc./tx
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $319.0M | $510.7M | $502.4M | $640.3M | $544.5M | $60.3M |
| Cost of Revenue | — | $281.1M | $389.6M | $378.9M | $631.9M | $305.6M | $50.9M |
| Gross Profit | — | $37.9M | $121.1M | $123.5M | $8.4M | $238.9M | $9.4M |
| Gross Margin | — | 11.9% | 23.7% | 24.6% | 1.3% | 43.9% | 15.6% |
| Operating Expenses | |||||||
| Research & Development | — | — | $11.8M | $7.2M | $27.0M | $7.7M | $5.3M |
| SG&A Expense | — | $159.2M | $113.7M | $108.1M | $213.3M | $60.5M | $14.6M |
| Operating Income | — | $-245.6M | $-142.1M | $9.0M | $-2.11B | $131.5M | $-6.3M |
| Operating Margin | — | -77.0% | -27.8% | 1.8% | -329.5% | 24.2% | -10.5% |
| Interest Expense | — | — | — | — | — | — | — |
| Pretax Income | — | $-288.0M | $-1.44B | $-245.8M | $-2.16B | $63.1M | $-12.2M |
| Income Tax Expense | — | $583.0K | $859.0K | $683.0K | $-17.1M | $15.8M | $0 |
| Net Income | — | $-288.6M | $-1.44B | $-246.5M | $-2.15B | $47.3M | $-12.2M |
| Net Margin | — | -90.5% | -281.6% | -49.1% | -335.2% | 8.7% | -20.2% |
| EPS (Basic) | — | $-0.88 | $-4.87 | $-0.65 | $-6.30 | $0.23 | $-0.14 |
| EPS (Diluted) | — | $-0.88 | $-4.87 | $-0.65 | $-6.30 | $0.20 | $-0.14 |
| Shares Outstanding (Basic) | 315.3M | 318.1M | 255.8M | 379.9M | 340.6M | 207.3M | 157.6M |
| Shares Outstanding (Diluted) | 315.3M | 318.1M | 255.8M | 379.9M | 340.6M | 233.3M | 157.6M |
| Dividends Per Share | — | — | — | — | — | — | — |